Mesoblast Ltd. (MESO), which is developing off-the-shelf cellular medicines for life-threatening inflammatory conditions, is planning to file a Biologics License Application for Ryoncil with the FDA next week.
Ryoncil is being developed for the treatment of children with steroid-refractory acute graft versus host disease (SR-aGVHD). It comprises of culture-expanded mesenchymal stem cells derived from the bone marrow of an unrelated donor.
Steroid-resistant or steroid-refractory acute graft-versus-host disease (SR-aGVHD) is one of the significant complications that can arise following allogeneic hematopoietic cell transplantation.
MESO has traded in a range of $1.61 to $10.24 in the last 1 year. The stock closed Friday's trading (June 28, 2024) at $6.81, down 0.58%.
For comments and feedback: editorial@rttnews.com